ImmuPharma eyes P140 licensing deal as scientific evidence mounts
ImmuPharma PLC (AIM:IMM, FRA:25I), the specialist drug discovery company, said it remained focused on landing a value-enhancing licensing deal for…
0,049€
-2,00%
Echtzeit-Aktienkurs ImmuPharma PLC
Bid:
Ask:
Nachrichten zur ImmuPharma PLC Aktie
ImmuPharma broadens P140 research and files international patent as it hunts for a deal
ImmuPharma PLC (AIM:IMM, FRA:25I), the specialist drug discovery company, has published fresh research suggesting its lead compound P140 could work…
Seeing Machines, Frontier IP, ImmuPharma, MP Evans, Ariana Resources, 88 Energy
…
ImmuPharma launches regulatory push for Kapiglucagon diabetes drug
ImmuPharma PLC (AIM:IMM, FRA:25I), the drug discovery company, has kicked off the regulatory groundwork needed to advance its Kapiglucagon diabetes...…
ImmuPharma reports patent progress and new data for P140 autoimmune platform
ImmuPharma shares rose on Friday after providing an update on P140, its autoimmune technology platform, pointing to progress on three…
ImmuPharma CEO on P140 progress and expanded pipeline with Kapiglucagon
…
AIM movers: ImmuPharma cash raising and CRISM Therapeutics orphan designation
Africa-focused investment company Tapir Holdings (LON: TAPH) joined AIM on 11 March. Trading in the shares has been limited. Around…
Oriole Resources, Rainbow Rare Earths, Powerhouse Energy, ImmuPharma, Polarean Imaging, Vaultz Capital
…
ImmuPharma, hVIVO, Ananda Pharma, Ondo InsurTech, SEEEN - Small Cap Week in Review
…
Ondo InsurTech, ImmuPharma, Oriole Resources, Empire Metals
…
ImmuPharma CEO Tim McCarthy shares latest developments with P140 platform, road ahead
…